ZNF12 Knockout cell line (A549)

Ubigene gene knockout cell lines mediated by optimized CRISPR-Cas9 technology provide reliable in vitro models for investigating gene function, signaling pathways, disease mechanisms, and therapeutic targets.

ZNF12 (zinc finger protein 12) encodes a nuclear transcriptional regulator containing a KRAB domain and eight C2H2-type zinc fingers. Through its DNA-binding zinc finger domains, ZNF12 is involved in developmental control of gene expression. The KRAB domain supports transcriptional regulatory activity, suggesting that ZNF12 contributes to repression or modulation of specific gene expression programs during cellular and developmental processes.

A549 is a human lung cancer cell line established in 1972 from an explanted lung tumor of a 58-year-old male patient. The cells exhibit characteristics of alveolar type II pulmonary epithelial cells, including the ability to synthesize lecithin through the cytidine diphosphocholine pathway. A549 cells have been described as originating from lung adenocarcinoma and are widely used as a model for studying lung cancer biology, pulmonary epithelial function, drug responses, and respiratory-related research.

Before delivery, each clone is authenticated by STR, tested for sterility and mycoplasma, and genotype‑verified by two‑round PCR‑sequencing. Comprehensive QC data accompany every shipment to support reproducible research.